A French company called Theraclion recently announced that it has received a CE Mark for its EchoPulse system, enabling their surgical robot to treat fibroadenomas — benign breast tumours — non-invasively, a first for this indication. The company originally applied their HIFU technology for the treatment of patients with pathologies in the thyroid and parathyroid glands. According to Jean-Yves Burel, CEO of Theraclion, “This market authorization in Europe will allow us to grow by creating surgery centres based on our echotherapy solution within leading hospitals and clinics. Other tumours besides breast fibroadenomas will be treated in a non-invasive manner in the near future.”
The inventor of the EchoPulse robot is François Lacoste, the company’s Chief Scientific Officer, who was recently awarded a United States patent (US 8,353,832). At the system’s core is a visualization and treatment unit that includes: an ultrasound transducer for real-time imaging of the target area; a HIFU emission device for treatment of the tumour; an articulated arm for easy positioning on the treatment area; and a motorized controller to perform precise positioning of the treatment head.
In addition, there is a disposable EPack that circulates fluid, ensuring both cooling of the treatment head and coupling of the visualization probe, thus providing optimal image quality. The patient lies on her side on the treatment bed while the surgeon — normally a gynaecologist — uses a touch screen to image the tumour in 3D, control the robot and ablate the lesion in a step-wise fashion. The focal point reaches a temperature of 85 degrees Celsius, hot enough to kill the tumour cells, and the operation takes no more than 40 minutes. The patient, who requires no anaesthesia and is mildly sedated, experiences no pain or skin damage and is discharged by the afternoon of the procedure.
So, with this ingenious device, ultrasound is used both to visualize and to treat the lesion. Now that’s rather nifty!
